TCRTHIGH SIGNALRISK10-K

TCRT significantly increased its outstanding share count by nearly 50% while highlighting acute liquidity concerns and shifting strategic focus to obesity and metabolic disorders.

The substantial dilution of outstanding shares from 1.6M to 2.4M suggests recent equity raises to address critical funding needs, which is confirmed by new risk language emphasizing the requirement for "substantial additional financial resources to continue as a going concern." The company appears to have pivoted away from previous strategic alternatives including potential dissolution, now focusing resources on a specific obesity and metabolic disorders program.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The company showed modest operational improvements with reduced operating losses and better cash flow from operations, while interest expenses declined meaningfully. However, current assets decreased notably while liabilities increased, and despite some cash position improvement, the overall liquidity picture remains concerning given the going-concern emphasis. The financial metrics suggest a company managing through a difficult transition period with limited resources.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+42.3%
-$5.0M-$2.9M

Operating cash flow surged 42.3% — exceptional cash generation, highest quality earnings signal.

Interest Expense
P&L
-39.1%
$3.2M$1.9M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Assets
Balance Sheet
-27.8%
$2.8M$2.0M

Current assets declined 27.8% — monitor working capital adequacy and short-term liquidity.

Cash & Equivalents
Balance Sheet
+26.9%
$1.1M$1.4M

Cash grew 26.9% — improving liquidity position supports investment and shareholder returns.

Total Liabilities
Balance Sheet
+17.5%
$692K$813K

Liabilities increased 17.5% — monitor debt-to-equity ratio and interest coverage.

Current Liabilities
Balance Sheet
+17.5%
$692K$813K

Current liabilities rose 17.5% — increased short-term obligations, watch current ratio.

Operating Income
P&L
+12.2%
-$4.8M-$4.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+10.8%
-$4.7M-$4.2M

Net income grew 10.8% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
(Exact Name of Registrant as Specified in Its Charter) Delaware 84-1475642 (State or Other Jurisdiction of Incorporation or Organization) (IRS Employer Identification No.) 501 E.
As o f March 31, 2026, there were 2,378,253 sh ares of the registrant s common stock, $0.001 par value per share, outstanding.
We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
We own the trademarks Alaunos Therapeutics , hunTR , and Ziopharm as well as the related graphic trademarks found on our website.
You should carefully review and consider the full discussion of our risk factors in the section titled Risk Factors in Part I, Item 1A of this Annual Report, particularly the sections captioned Risks Related to Our Strategic Reprioritization, Risks Related to Our Liquidity and Capital Resources, and Risks Related to Our Obesity and Metabolic Program.
+7 more — sign up free →
REMOVED
As of March 31, 2025, there w ere 1,601,252 shares of the registrant s common stock, $0.001 par value per share, outstanding.
We own the trademarks Alaunos , hunTR , and Ziopharm as well as the graphic trademark found on our website.
You should carefully review and consider the full discussion of our risk factors in the section titled Risk Factors in Part I, Item 1A of this Annual Report.
Some of the more significant risks include the following: Our strategic reprioritization may not be successful, may not yield the desired results and we may be unsuccessful in identifying and implementing any strategic transaction.
If a strategic transaction is not consummated, our Board of Directors may decide to pursue a dissolution and liquidation.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →